What is Daré Bioscience?
Headquartered in San Diego, California, Daré Bioscience is a clinical-stage biopharmaceutical company dedicated to the development of innovative products for women’s health. Its comprehensive portfolio spans critical therapeutic areas, including contraception, menopause, fertility, pelvic pain, vaginal health, and infectious disease. The company achieved a significant commercial milestone with the FDA approval of XACIATO, a vaginal gel indicated for bacterial vaginosis. Beyond this, the firm is actively advancing high-potential candidates such as Ovaprene, a hormone-free monthly contraceptive, and Sildenafil Cream 3.6%, which targets female sexual arousal disorder. By focusing on underserved segments of the healthcare market, Daré Bioscience leverages a unique business model that prioritizes high-impact, patient-centric innovation.
How much funding has Daré Bioscience raised?
Daré Bioscience has raised a total of $37.6M across 6 funding rounds:
Multiple Rounds
$22.1M
Other Financing Round
$12M
Grant
$2.5M
Unspecified
$908K
Share Placement (2020): $6.8M, investors not publicly disclosed
Debt (2020): $350K led by PPP
Share Placement (2020): $15M supported by Lincoln Park Capital Fund , LLC
Other Financing Round (2023): $12M, investors not publicly disclosed
Grant (2024): $2.5M, investors not publicly disclosed
Unspecified (2026): $908K with participation from Eunice Kennedy Shriver National Institute of Child Health and Human Development
Key Investors in Daré Bioscience
Eunice Kennedy Shriver National Institute of Child Health and Human Development
A prominent research institute under the National Institutes of Health that supports scientific discovery and clinical research to improve the health of children, adults, and families.
Lincoln Park Capital Fund, LLC
An institutional investment firm specializing in providing growth capital to emerging companies through structured equity financing solutions.
Undisclosed Investor
An undisclosed investor participating in the funding round to support the company's long-term strategic objectives.
What's next for Daré Bioscience?
With the recent influx of $908K, Daré Bioscience is well-positioned to accelerate its clinical development programs and optimize its commercialization strategy for its late-stage pipeline. The company is expected to prioritize the advancement of DARE-HRT1, its intravaginal hormone therapy for postmenopausal women, while simultaneously scaling its market presence for existing products. Strategic focus will likely remain on achieving key regulatory milestones and exploring potential partnerships that could enhance the distribution and adoption of its therapeutic offerings. As the company matures, the emphasis will shift toward sustainable revenue generation and the continued expansion of its intellectual property portfolio, reinforcing its status as a leader in the women's health innovation ecosystem.
See full Daré Bioscience company page
